The role of BRCA1 and BRCA2 in prostate cancer

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 409-414

  Castro, Elena ^a,b   Eeles, Rosalind ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

BRCA1; BRCA2; prostate cancer

Indexed keywords

CANCER RISK; GENE MUTATION; HETEROZYGOTE; HUMAN; MALE; ONCOGENE; PREDICTION; PREDICTOR VARIABLE; PROSTATE CANCER; REVIEW; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 84860858981     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2011.150     Document Type: Review

References (110)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007; 14: 78-85. (Pubitemid 46172395)
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992; 89: 3367-3371.
5. Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis 1999; 2: 9-15. (Pubitemid 29096322)
6. Edwards SM, Eeles RA. Unravelling the genetics of prostate cancer.Am J Med Genet C Semin Med Genet 2004; 129C: 65-73. (Pubitemid 38989133)
7. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J et al. Environmental and heritable factors in the causation of cancer-Analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85. (Pubitemid 30451850)
8. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-649. (Pubitemid 46676108)
9. Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-1060.
10. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-658. (Pubitemid 43927306)
11. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, GuyMet al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-321. (Pubitemid 351311772)
12. Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, GuyMet al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-1121.
13. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-791.
14. Gudmundsson J, Sulem P, Gudbjartsson DF, Blondal T, Gylfason A et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-1126.
15. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-283. (Pubitemid 351311771)
16. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-983. (Pubitemid 47185170)
17. Sun J, Zheng SL, Wiklund F, Isaacs SD, Purcell LD, et al. Evidence for two independent prostate cancer risk-Associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-1155.
18. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-3875.
19. Takata R, Akamatsu S, Kubo M, Takahashi A, Hosono N et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-754.
20. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-315. (Pubitemid 351311773)
21. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12. (Pubitemid 36056838)
22. Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br J Cancer 2007; 97: 826-831. (Pubitemid 47396283)
23. Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, CastroE et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230-1234.
24. Consortium TB. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316.
25. Ostrander EA, Kwon EM, Stanford JL. Genetic susceptibility to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 1761-1764. (Pubitemid 44664246)
26. Easton DF, Schaid DJ, Whittemore AS, Isaacs WJ. Where are the prostate cancer genes? A summary of eight genome wide searches. Prostate 2003; 57: 261-269. (Pubitemid 37487071)
27. Schaid DJ, McDonnell SK, Zarfas KE, Cunningham JM, Hebbring S et al. Pooled genome linkage scan of aggressive prostate cancer: Results from the International Consortium for Prostate Cancer Genetics. Hum Genet 2006; 120: 471-485. (Pubitemid 44669782)
28. Huang SP, Ting WC, Chen LM, Huang LC, Liu CC et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol 17: 312-322.
29. Strom SS, Gu Y, Zhang H, Troncoso P, Babaian RJ et al. Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients. Prostate 2004; 60: 343-351. (Pubitemid 39050655)
30. Larson BT, Magi-Galluzzi C, Casey G, Plummer SJ, Silverman R et al. Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants. J Urol 2008; 179: 1344-1348.
31. Huang SP, Huang LC, Ting WC, Chen LM, Chang TY et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 3068-3074.
32. Perez CA, Chen H, Shyr Y, Courtney R, Zheng W et al. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer. J Urol 2011; 183: 2062-2069.
33. Morote J, Del Amo J, Borque A, Ars E, Hernández C et al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J Urol 2010; 184: 506-511.
34. Goh CL, Schumacher FR, Easton D, Muir K, Henderson B et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med; e-pub ahead of print 2012 Feb 6; doi: 10.1111/j.1365-2796.2012.02511.x.
35. Crawford ED. Epidemiology of prostate cancer. Urology 2003; 62: 3-12. (Pubitemid 38050194)
36. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993; 150: 797-802. (Pubitemid 23241269)
37. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic populationbased assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600-1608. (Pubitemid 24336346)
38. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-864. (Pubitemid 36331852)
39. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-Analysis. Int J Cancer 2003; 107: 797-803. (Pubitemid 37339734)
40. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: A meta-Analysis. Cancer 2003; 97: 1894-1903. (Pubitemid 36397263)
41. Ostrander EA, Johannesson B. Prostate cancer susceptibility loci: Finding the genes. Adv Exp Med Biol 2008; 617: 179-190.
42. Langeberg WJ, Isaacs WB, Stanford JL. Genetic etiology of hereditary prostate cancer. Front Biosci 2007; 12: 4101-4110.
43. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 Spec No 1: R103-21. (Pubitemid 38443804)
44. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 235-237.
45. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71. (Pubitemid 24345325)
46. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088-2090. (Pubitemid 24325690)
47. Anderson DE, Badzioch MD. Breast cancer risks in relatives of male breast cancer patients. J Natl Cancer Inst 1992; 84: 1114-1117.
48. Tulinius H, Egilsson V, Olafsdottir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. BMJ 1992; 305: 855-857.
49. Thiessen EU. Concerning a familial association between breast cancer and both prostatic and uterine malignancies. Cancer 1974; 34: 1102-1107.
50. Wooster R, Weber BL. Breast and ovarian cancer.N Engl J Med 2003; 348: 2339-2347. (Pubitemid 36638109)
51. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S et al. Cancer risks in BRCA2 families: Estimates for sites other than breast and ovary. J Med Genet 2005; 42: 711-719. (Pubitemid 41306062)
52. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-1365. (Pubitemid 35154140)
53. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864-5874. (Pubitemid 44453442)
54. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006; 34: 633-645. (Pubitemid 44796392)
55. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-182. (Pubitemid 34161138)
56. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
57. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM et al. Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res 2000; 60: 5946-5949.
58. Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T. Androgen regulation of the androgen receptor coregulators.BMC Cancer 2008; 8: 219.
59. Schayek H, Haugk K, Sun S, True LD, Plymate SR et al. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 2009; 15: 1558-1565.
60. Francis JC, McCarthy A, Thomsen MK, Ashworth A, Swain A. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet 2010; 6: E1000995.
61. Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E et al. Loss of BRCA2 promotes prostate cancer cell invasion through up-regulation of matrix metalloproteinase-9. Cancer Sci 2008; 99: 553-563. (Pubitemid 351228573)
62. Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 2010; 16: 3340-3348.
63. Castro E et al. Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome. ASCO Meet Abstr 2011; 29: 1517.
64. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, Jonasson JG, Olafsdóttir EJ et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 929-935. (Pubitemid 47073499)
65. Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res 2010; 16: 2115-2121.
66. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29: 3659-3668.
67. Sebastian de Bono J, Sandhu S, Attard G. Beyond hormone therapy for prostate cancer with PARP inhibitors. Cancer Cell 2011; 19: 573-574.
68. Johannsson O, Loman N, Möller T, Kristoffersson U, Borg A et al. Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers. Eur J Cancer 1999; 35: 1248-1257. (Pubitemid 29359186)
69. Eerola H, Pukkala E, Pyrhönen S, Blomqvist C, Sankila R et al. Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland). Cancer Causes Control 2001; 12: 739-746. (Pubitemid 32803500)
70. Bermejo JL, Perez AG, Hemminki K. Contribution of the defectiveBRCA1, BRCA2 and CHEK2 genes to the familial aggregation of breast cancer: A simulation study based on the Swedish family-cancer database. Hered Cancer Clin Pract 2004; 2: 185-191.
71. Sigurdsson S, Thorlacius S, Tomasson J, Tomasson L, Benediktsdottir K et al. BRCA2 mutation in Icelandic prostate cancer patients.J Mol Med (Berl) 1997; 75: 758-761. (Pubitemid 27451978)
72. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343: 692-695. (Pubitemid 24087847)
73. Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J et al. Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer. Clin Cancer Res 2007; 13: 839-843. (Pubitemid 46340357)
74. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based casecontrol studies of ovarian cancer. Am J Hum Genet 1997; 60: 496-504. (Pubitemid 27097597)
75. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer 2002; 86: 76-83. (Pubitemid 34146344)
76. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694-1706. (Pubitemid 44942707)
77. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14: 185-187. (Pubitemid 26338801)
78. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996; 14: 188-190. (Pubitemid 26338802)
79. Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 2000; 83: 463-466. (Pubitemid 30487858)
80. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 2004; 10: 2918-2921. (Pubitemid 38619665)
81. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336: 1401-1408. (Pubitemid 27208598)
82. Wilkens EP, Freije D, Xu J, Nusskern DR, Suzuki H et al. No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. Prostate 1999; 39: 280-284. (Pubitemid 29244502)
83. Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999; 40: 172-177. (Pubitemid 29334865)
84. Giusti RM, Rutter JL, Duray PH, Freedman LS, KonichezkyMet al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003; 40: 787-792. (Pubitemid 37311080)
85. Hubert A, Peretz T, Manor O, Kaduri L, WienbergNet al. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999; 65: 921-924. (Pubitemid 30468737)
86. Agalliu I, Gern R, Leanza S, Burk RD. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. Clin Cancer Res 2009; 15: 1112-1120.
87. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res 1996; 56: 3663-3665. (Pubitemid 26272009)
88. Edwards SM, Evans DG, Hope Q, Norman AR, Barbachano Y et al. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer 2010; 103: 918-924.
89. Thorne H, Willems AJ, Niedermayr E, Hoh IM, Li J et al. Decreased prostate cancerspecific survival of men with BRCA2 mutations from multiple breast cancer families. Cancer Prev Res (Phila) 2011; 4: 1002-1010.
90. Narod SA, Neuhausen S, Vichodez G, Armel S, Lynch HT et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371-374.
91. Mitra A, Fisher C, Foster CS, Jameson C, Barbachanno Y et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98: 502-507. (Pubitemid 351161242)
92. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, ChiaDet al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
93. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-1328.
94. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-732.
95. Mitra AV, Bancroft EK, Bancroft Y, Page EC, Foster CS et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJU Int 2011; 107: 28-39.
96. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-903. (Pubitemid 30624678)
97. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003; 88: 1285-1291. (Pubitemid 36606348)
98. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120. (Pubitemid 351317449)
99. Byrski T, Gronwald J, Huzarski T, Grzybowska E, BudrykMet al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
100. Tan DS, Marchio C, Reis-Filho JS. Hereditary breast cancer: From molecular pathology to tailored therapies. J Clin Pathol 2008; 61: 1073-1082.
101. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R et al. 'BRCAness' syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-5536.
102. Yang D, Khan S, Sun Y, Hess K, Shmulevich I et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306: 1557-1565.
103. Gallagher DJ, Cronin AM, Milowsky MI, Morris MJ, Bhatia J et al. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int 2011; 109: 713-719.
104. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963; 11: 39-43.
105. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 882-893. (Pubitemid 39128102)
106. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921. (Pubitemid 40559006)
107. Ashworth A. A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-3790.
108. Fong PC, Boss DS, Yap TA, Tutt A, Wu P et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
109. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M et al. Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28: 2512-2519.
110. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 2010; 376: 235-244.